-77%

est. 2Y upside i

HealthcarePre-Seed

Digital hematology

Rank

#955

Sector

Digital Health, Healthcare Technology Systems

Est. Liquidity

~7Y

Data Quality

Data: Low

This opportunity presents extremely high risk due to a critical funding gap and the long, costly regulatory path for digital therapeutics, yet offers substantial upside if the company can secure significant capital and successfully navigate clinical and regulatory hurdles leveraging its strong niche network.

Last updated: February 16, 2026

Bull (27%)+400%

Successful clinical trials, regulatory approval, and strong commercialization lead to significant market penetration and acquisition by a large pharma or health tech company.

Base (33%)+50%

Achieves initial regulatory clearance and modest commercial traction, leading to a follow-on funding round at a higher valuation or a small strategic acquisition.

Bear (40%)-90%

Fails to secure additional funding, clinical trials are unsuccessful, or regulatory hurdles prove insurmountable, leading to closure or a fire sale.

Est. time to liquidity~7.0 years

Community

Valuation Sentiment

Our model estimates -77% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.